Potential takeover target?, page-3

One of the things TLX does in its presentations- along with every other bio- is put up a set of "sector benchmarks", presumably to induce slavering fantasies in retail investors like us. The three examples of companies getting bought out had values $2 billion or more.

I still maintain that where we are at the end of the year is crucial: if there's an FDA approved product making good money, that will make things interesting.

Having seen other companies struggle with issues like manufacturing, it means a lot to me to see that TLX is getting the product out there already.